CD86 and neoplasm: Ipilimumab binds to CTLA-4 on T-cells, which inhibits its ability to bind to CD80/CD86, allowing for the expansion of a repertoire of antigen-specific anti-tumor cytotoxic CD8+ T-cells and CD4+ T-cells, which corresponds to an improved anti-tumor immune response [372,373,374,375,376,377,378].